RARRES2 levels negatively, whereas CMKLR1 levels positively influenced both OS and progression-free survival (PFS) of ovarian cancer patients, and GPR1 and CCRL2 levels did not affect patients’ OS or PFS. This evidence concerns the gene CMKLR2 and ovarian cancer.